Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
UPC · Nasdaq · United States · Pharmaceutical Preparations
In shortUniverse Pharmaceuticals INC is loss-making, burns cash and holds more cash than debt, with revenue shrinking (−22.4% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -16.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -20.6% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -7.2% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -4.0% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.07× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.04× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -10.08× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 7.37 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -29.8% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 35950.0% | 0/100 |
| Operating margin volatility | 23.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 663.4% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
2 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 48 | 40 | 32,309 | 23,024 | 17,859 |
| Cost of revenue | 23 | 18 | 21,994 | 16,953 | 11,558 |
| Gross profit | 25 | 22 | 10,315 | 6,072 | 6,301 |
| Research & development | 5.5 | 7.6 | 4,859 | 3,031 | 672 |
| Operating income | 14 | (7) | (3,966) | (8,020) | (2,916) |
| Interest expense | 0.1 | 0.2 | 190 | 305 | 289 |
| Pre-tax income | 14 | (7.1) | (4,327) | (8,121) | (3,672) |
| Income tax | 2.4 | 0.8 | 2,254 | 607 | – |
| Net income | 11 | (7.9) | (6,581) | (8,727) | (3,672) |
| Diluted EPS | $3.58 | −$1,309.11 | −$1,089.21 | −$626.96 | −$8.06 |
| Diluted shares (millions) | 3.2 | 0 | 0 | 0 | 0.5 |
2 older years available with the 10-year history. Essential plan, from €8.25/month →
7.37 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Sep 30, 2025 · Data updated Jan 29, 2026